Twelve germline variants were LoF (AARSD1, ACSM3, ERI2, CECR2, CRYGA, DNAH7, ETV4, HOXC4, MAMDC4, NEBL, PRSS56, and TBXAS1), standing out a stop gain in HOXC4, which was not previously reported in any germline database, including a cohort of Brazilians (ABRAOM), and an indel in the PRSS56 (ClinVar 31077), both variants already reported in liver cancer samples (ICGC). This evidence concerns the gene NEBL and liver cancer.